First AD

Second AD

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Inside The Clinic: HR+/HER2- Metastatic Breast Cancer

Insights

Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.

Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC

Overview of HR+/HER2- Metastatic Breast Cancer (mBC)

Case Presentation: A 72-Year-Old Woman With HR+/HER2- mBC

Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC

Case Presentation: A 56-Year-Old Woman With ER+/HER2- mBC

Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC

Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC

Remaining Unmet Needs for Patients With HR+/HER2- mBC

Advice For Providers Caring for Patients With HR+/HER2- mBC